Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CKEC, ORFG, ELGX, PWRM, ADUS - Stock Report from CRWEFinance.com

crwefinancelogo2

 

signup3m

 

Carmike Cinemas Inc. (Nasdaq:CKEC) a leading DIGITAL cinema and 3D motion picture exhibitor, announced that it will be working with the Garrett Moore Company out of Dallas, Texas, pending zoning approval from the local authorities, to build a 12-screen theatre with 2,330 seats. The theatre will feature a new Carmike state-of-the-art entertainment complex to be located at The Walk in the Tulsa Hills Development, on Highway 75 and 81st Street. Carmike’s Next Level In Cinema will feature THE BIG D DIGITAL EXPERIENCE, which will immerse our patrons in the ultimate sight and sound movie going adventure.

Carmike Cinemas, Inc. operates as a motion picture exhibitor in the United States. It shows films on a first-run basis, as well as operates discount theatres. The company serves small to mid-size non-urban markets.

***********

orfg_logo203x87

Orofino Gold Corp. (PINK:ORFG) has several Gold development properties in Colombia, a current hot spot of gold production in the world markets. The early adopters, who wisely purchased their positions before the masses come, will sleep well at night while others fret and worry as they watch the purchasing power of their savings evaporate like water in the desert. Gold offers a safe way to hedge against these falling fait currencies (backed by faith and nothing else). But for a little more leverage — and a lot more profit potential — invest in a junior gold stock.

Gold’s Usefulness as safe haven: The geo-political and world economic structure is currently undergoing major change-some have even called the situation an “upheaval.” This means that the investment outlook, particularly for certain parts of the world, is more unpredictable than usual. Under these circumstances, it is logical to conclude that certain investment portfolios should include real (non-paper) assets such as commodities for protection against a potential decline in the paper markets.

It is reasonably believed that the five plus high grade producing gold targets will produce 1+ million ounces each and with Silver and Copper credits the formulae above would be conservative. Gold is the most malleable and ductile of all metals; a single gram can be beaten into a sheet of 1 square meter, or an ounce into 300 square feet. Gold leaf can be beaten thin enough to become translucent. The opportunity looks like this ….Orofino Gold Corp. with 1 million ounces; the share price would be with (80,000,000 shrs out) 1 million ounce at a conservative $1,000 = $ 1 billion divided by 80 million shares = $12.50/share (Orofino has only 60,000,000 shrs outstanding now).

Orofino Gold Corp. is a China based gold producer with one producing gold mine in Colombia and an option on a strong portfolio of small producers and development/exploration assets in Colombia.

***********

Endologix Inc. (Nasdaq:ELGX) announced that John McDermott, President and Chief Executive Officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Conference Date: Wednesday, January 12, 2011 Time: 4:30 p.m. PT. An audio Web cast of the Company's presentation will be available by visiting the investor relations section of Endologix's Web site at endologix.com.

Endologix, Inc. develops, manufactures, markets, and sells minimally invasive treatments for aortic disorders. Its flagship product, the Powerlink System, is an endovascular stent graft for the treatment of abdominal aortic aneurysms, a weakening of the wall of the aorta, an artery in the body.

***********

power3

Power3 Medical Products, Inc. (OTCBB:PWRM) recently disclosed that Power3 delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials. Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which Power3 has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which Power3 is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

***********

Addus HomeCare Corp (Nasdaq:ADUS) announced the appointment of Daniel Schwartz as Chief Operating Officer, effective January 19, 2011. Mark Heaney, President and Chief Executive Officer of Addus HomeCare, stated, "We are very excited to have Daniel join our executive team. With 15 years of operational experience at Sunrise Senior Living, a NYSE-traded senior living company with revenues of approximately $1.4 billion in 2009, and proven success in a decentralized, multi-site business serving seniors, Daniel will be responsible for improving profitability and driving growth in our Home & Community Services and Home Health Divisions, and helping to realize the full potential of our integrated model.

Addus HomeCare Corporation provides a range of social and medical services to individuals in the home.

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK:ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).